cardiac dysfunction heart failure
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In the current BLOC-II study, we will invite all women who previously took part in the BLOC-I study. Inclusion criteria of that study were: females diagnosed with stage I-III BC at least five years ago or local or locoregional recurrence of BC at least five years ago; treatment with chemotherapy and/or radiotherapy. BC survivors were matched with women of the same age (±1 year) who had the same GP, but who had no history of cancer or cancer treatment (chemotherapy or radiotherapy)
Exclusion criteria
Exclusion criteria: Patients unfit to travel to the hospital or fill out questionnaires due to severe mental or physical illness, based on assessment by their GP, will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular systolic and diastolic cardiac dysfunction. Systolic cardiac dysfunction is defined as a LVEF | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinically used LVEF cut-off points = 34 ml/m2). - Diagnoses of cardiovascular disease - Rate of deterioration of cardiac function by change in LVEF - Global Longitudinal Strain (GLS) - Biomarkers (e.g. NT-proBNP) Covariates assessed during new measurement - Patient characteristics: age, BMI, menopausal state, smoking behavior, physical activity level, - Changes in lifestyle - Symptoms of anxiety, depression and fatigue (HADS & MFI-20) - Use of cardiovascular medication at time of BLOC-II study Background variables / predictors (assessed during BLOC-I study) - Treatment characteristics: administered chemotherapy regimens, cumulative dosages, antihormone treatments, and radiotherapy site (left or right), RT dosage on LV cardiac substructures - Cardiovascular risk factors - Use of cardiovascular medication | — |
Countries
Netherlands
Outcome results
None listed